Scott Royal
President & Chief Executive Officer
Contact
ScottRoyal@westat.comOverview
Scott Royal, PhD, is the President and Chief Executive Officer of Westat. Royal’s adaptive approach, emphasis on innovation, and strong communication have guided Westat since he joined in November 2017 as President. Royal was elected to the Board of Directors in May 2018 and became CEO in 2020. Royal’s leadership draws on his background in public health research and data-driven decision-making to address organizational needs and client priorities.
Royal fosters a culture of collaboration and excellence that drives quality, high-impact work. He prioritizes clear, consistent communication and encourages adaptability to meet evolving client needs. Recognizing technology and data science as critical to Westat’s research mission, Royal ensures IT capabilities directly support researchers in their work.
Royal’s hands-on background in public health enables him to lead with insight, anticipate the real-world implications of research, and understand staff challenges. Earlier in his career, he conducted research projects and helped organizations build capacity in public health and epidemiological research.
Royal currently serves on the Board of Directors for the Children’s Inn at the National Institutes of Health and previously served on the Beebe Medical Foundation Board in Lewes, Delaware.
.
Education
- PhD, Bloomberg School of Public Health at Johns Hopkins University
- MPH, Bloomberg School of Public Health at Johns Hopkins University
- BA, Furman University
-
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine
Contemporary Clinical Trials
January 2023
N.A. Scott, C. Sadowski, A. Vernon, B. Arevalo, K. Beer, A. Borisov, J.A. Cayla, et al.
DOILink for: Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine -
Theory, methods, and operational results of the Young Women's Health History Study: A study of young-onset breast cancer incidence in Black and White women
32,
Cancer Causes and Control
January 2021
E.M. Velie, L.R. Marcus, D.R. Pathak, A.S. Hamilton, R. DiGaetano, R. Klinger, B. Gollapudi, et al.
DOILink for: Theory, methods, and operational results of the Young Women's Health History Study: A study of young-onset breast cancer incidence in Black and White women -
Improved veteran access to care through the Veteran Health Information Exchange (VHIE) Retail Immunization Coordination Project
January 2016
N. Botts, E. Pan, L. Olinger, M. Donahue, N. Hsing
SOURCEImproved veteran access to care through the Veteran Health Information Exchange (VHIE) Retail Immunization Coordination Project